HomeCompareTHTX vs VIG

THTX vs VIG: Dividend Comparison 2026

THTX yields 59.00% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THTX wins by $587.8K in total portfolio value
10 years
THTX
THTX
● Live price
59.00%
Share price
$3.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$620.2K
Annual income
$143,088.77
Full THTX calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — THTX vs VIG

📍 THTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHTXVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THTX + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THTX pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THTX
Annual income on $10K today (after 15% tax)
$5,014.75/yr
After 10yr DRIP, annual income (after tax)
$121,625.45/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, THTX beats the other by $121,473.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THTX + VIG for your $10,000?

THTX: 50%VIG: 50%
100% VIG50/50100% THTX
Portfolio after 10yr
$326.3K
Annual income
$71,633.96/yr
Blended yield
21.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on THTX right now

THTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-8.8
Piotroski
5/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THTX buys
0
VIG buys
9
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$VIG▲ Buy$1,001 - $15,0002024-05-16
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002023-12-28
Ro Khanna🏢 House$VIG▼ Sell$15,001 - $50,0002023-05-04
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
Joe Courtney🏢 House$VIG▼ Sell$1,001 - $15,0002020-10-09
K. Michael Conaway🏢 House$VIG▼ Sell$50,001 - $100,0002020-09-08
K. Michael Conaway🏢 House$VIG▲ Buy$15,001 - $50,0002020-05-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHTXVIG
Forward yield59.00%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$620.2K$32.4K
Annual income after 10y$143,088.77$179.15
Total dividends collected$512.6K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: THTX vs VIG ($10,000, DRIP)

YearTHTX PortfolioTHTX Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$16,600$5,899.71$11,304$163.92+$5.3KTHTX
2$26,914$9,152.65$12,759$166.33+$14.2KTHTX
3$42,667$13,869.04$14,382$168.52+$28.3KTHTX
4$66,202$20,548.25$16,192$170.52+$50.0KTHTX
5$100,633$29,796.73$18,210$172.34+$82.4KTHTX
6$150,008$42,330.45$20,460$173.98+$129.5KTHTX
7$219,480$58,971.49$22,968$175.48+$196.5KTHTX
8$315,482$80,637.85$25,763$176.83+$289.7KTHTX
9$445,892$108,326.32$28,878$178.05+$417.0KTHTX
10$620,193$143,088.77$32,350$179.15+$587.8KTHTX

THTX vs VIG: Complete Analysis 2026

THTXStock

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Full THTX Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this THTX vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THTX vs SCHDTHTX vs JEPITHTX vs OTHTX vs KOTHTX vs MAINTHTX vs DGROTHTX vs NOBLTHTX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.